A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms
(1) Objective: hypercoagulability in patients with malignant neoplasm were evaluated to examine the relationship with thrombosis. (2) Methods: clot waveform analysis (CWA)—activated partial thromboplastin time (APTT) and CWA—small amount of tissue factor induced FIX activation (sTF/FIXa) assays were...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/587b4b066fa54de4aa97d106a485f733 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:587b4b066fa54de4aa97d106a485f733 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:587b4b066fa54de4aa97d106a485f7332021-11-25T18:01:58ZA Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms10.3390/jcm102253522077-0383https://doaj.org/article/587b4b066fa54de4aa97d106a485f7332021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5352https://doaj.org/toc/2077-0383(1) Objective: hypercoagulability in patients with malignant neoplasm were evaluated to examine the relationship with thrombosis. (2) Methods: clot waveform analysis (CWA)—activated partial thromboplastin time (APTT) and CWA—small amount of tissue factor induced FIX activation (sTF/FIXa) assays were performed in 92 patients with malignant neoplasm and the relationship between hypercoagulability and thrombosis was retrospectively examined. (3) Results: The study population included 92 patients with malignant neoplasms. Twenty-six (28.3%) had thrombotic diseases and 9 (9.8%) patients died within 28 days after the CWA. The peak time of the CWA-APTT could not show hypercoagulability in patients with malignant neoplasms. There were almost no significant differences in the peak times of the sTF/FIXa among patients with malignant neoplasms and healthy volunteers. In contrast, the peak heights of the CWA-sTF/FIXa in patients with various malignant neoplasms were significantly higher than those in healthy volunteers. Furthermore, among patients with malignant neoplasms, the peak heights of the sTF/FIXa in patients with thrombosis were significantly higher than those in patients without thrombosis. (4) Conclusions: although the routine APTT cannot evaluate the hypercoagulability, the peak heights of CWA-sTF/FIXa were significantly high in patients with malignant neoplasms, especially in those with thrombosis, suggesting that an elevated peak height of the CWA-sTF/FIXa may be a risk factor for thrombosis.Mayu KobayashiHideo WadaShunsuke FukuiHiroki MizutaniYuhuko IchikawaKatsuya ShirakiIsao MoritaniHidekazu InoueMotomu ShimaokaHideto ShimpoMDPI AGarticleCWAAPTTsTF/FIXacancerthrombosisMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5352, p 5352 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
CWA APTT sTF/FIXa cancer thrombosis Medicine R |
| spellingShingle |
CWA APTT sTF/FIXa cancer thrombosis Medicine R Mayu Kobayashi Hideo Wada Shunsuke Fukui Hiroki Mizutani Yuhuko Ichikawa Katsuya Shiraki Isao Moritani Hidekazu Inoue Motomu Shimaoka Hideto Shimpo A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms |
| description |
(1) Objective: hypercoagulability in patients with malignant neoplasm were evaluated to examine the relationship with thrombosis. (2) Methods: clot waveform analysis (CWA)—activated partial thromboplastin time (APTT) and CWA—small amount of tissue factor induced FIX activation (sTF/FIXa) assays were performed in 92 patients with malignant neoplasm and the relationship between hypercoagulability and thrombosis was retrospectively examined. (3) Results: The study population included 92 patients with malignant neoplasms. Twenty-six (28.3%) had thrombotic diseases and 9 (9.8%) patients died within 28 days after the CWA. The peak time of the CWA-APTT could not show hypercoagulability in patients with malignant neoplasms. There were almost no significant differences in the peak times of the sTF/FIXa among patients with malignant neoplasms and healthy volunteers. In contrast, the peak heights of the CWA-sTF/FIXa in patients with various malignant neoplasms were significantly higher than those in healthy volunteers. Furthermore, among patients with malignant neoplasms, the peak heights of the sTF/FIXa in patients with thrombosis were significantly higher than those in patients without thrombosis. (4) Conclusions: although the routine APTT cannot evaluate the hypercoagulability, the peak heights of CWA-sTF/FIXa were significantly high in patients with malignant neoplasms, especially in those with thrombosis, suggesting that an elevated peak height of the CWA-sTF/FIXa may be a risk factor for thrombosis. |
| format |
article |
| author |
Mayu Kobayashi Hideo Wada Shunsuke Fukui Hiroki Mizutani Yuhuko Ichikawa Katsuya Shiraki Isao Moritani Hidekazu Inoue Motomu Shimaoka Hideto Shimpo |
| author_facet |
Mayu Kobayashi Hideo Wada Shunsuke Fukui Hiroki Mizutani Yuhuko Ichikawa Katsuya Shiraki Isao Moritani Hidekazu Inoue Motomu Shimaoka Hideto Shimpo |
| author_sort |
Mayu Kobayashi |
| title |
A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms |
| title_short |
A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms |
| title_full |
A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms |
| title_fullStr |
A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms |
| title_full_unstemmed |
A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms |
| title_sort |
clot waveform analysis showing a hypercoagulable state in patients with malignant neoplasms |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/587b4b066fa54de4aa97d106a485f733 |
| work_keys_str_mv |
AT mayukobayashi aclotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT hideowada aclotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT shunsukefukui aclotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT hirokimizutani aclotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT yuhukoichikawa aclotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT katsuyashiraki aclotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT isaomoritani aclotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT hidekazuinoue aclotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT motomushimaoka aclotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT hidetoshimpo aclotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT mayukobayashi clotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT hideowada clotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT shunsukefukui clotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT hirokimizutani clotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT yuhukoichikawa clotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT katsuyashiraki clotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT isaomoritani clotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT hidekazuinoue clotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT motomushimaoka clotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms AT hidetoshimpo clotwaveformanalysisshowingahypercoagulablestateinpatientswithmalignantneoplasms |
| _version_ |
1718411680564641792 |